DHA Enterprise-Wide Commercial Solutions Opening (CSO)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY (DHA)
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT003826SC005
NAICS
-
Classification Code
-
Additional Details
Documents2
The Defense Health Agency (DHA), a component of the U.S. Department of Defense, has issued a Special Notice announcing the DHA Enterprise-Wide Commercial Solutions Opening (CSO), under procurement identifier HT003826SC005. This CSO establishes the framework for competitive procedures the government will use to award contracts and agreements for commercial solutions that address the agency’s evolving needs. The CSO is authorized under several statutory authorities, including 10 U.S.C. §§ 3201, 3458, 4021, 4022, and 4023, as amended, and is further updated in accordance with Section 1823 of the National Defense Authorization Act for Fiscal Year 2026.
The primary objective of this CSO is to solicit proposals for commercial products, commercial services, and non-developmental items that are either currently available in the marketplace or can be readily modified to meet DHA’s requirements. The intent is to leverage innovative, commercially available capabilities to support the agency’s mission, which encompasses a broad range of health-related functions for the Department of Defense.
Under this CSO, the government will periodically issue specific Areas of Interest (AoIs). Each AoI will detail the particular problem statement or objectives, the statutory authority for the solicitation, evaluation and review criteria, submission requirements, and anticipated timelines for award. Contractors should note that AoIs may be posted, extended, or revised at any time during the open period of the CSO, allowing for ongoing opportunities to propose solutions aligned with DHA’s priorities.
The scope of potential awards under this CSO is expansive, covering basic, applied, and advanced research projects, prototyping and production agreements, and procurements for experimental purposes. The CSO is designed to accommodate a wide range of commercial solutions, provided they are relevant to DHA’s operational needs and can be delivered in accordance with federal acquisition regulations and other applicable authorities.
The place of performance for awarded contracts or agreements is Falls Church, Virginia, though the nature of the work may allow for flexibility depending on the specific requirements of each AoI.
This CSO will remain open for submissions until August 6, 2027, unless amended by the issuing office. Interested parties are encouraged to monitor the CSO for new or updated AoIs and to review the specific requirements and evaluation criteria outlined in each.
The contracting entity for this opportunity is the Defense Health Agency (DHA), a federal agency under the Department of Defense. The primary points of contact for this notice are Elizabeth Holten ([email protected]) and Lacey Lockard ([email protected]), who can provide further information regarding the CSO and submission process.
This procurement is classified as a Special Notice and is posted on SAM.gov under Opportunity ID 12815e3a7e814d11825cdf96242e2c0f. Contractors interested in pursuing this opportunity should review the full notice and any associated attachments available at https://sam.gov/opp/12815e3a7e814d11825cdf96242e2c0f/view.
In summary, the DHA Enterprise-Wide CSO represents a significant opportunity for commercial vendors to propose innovative solutions that can enhance the capabilities of the Defense Health Agency. The open and flexible nature of the CSO, combined with the agency’s broad mission scope, makes this an attractive vehicle for companies offering cutting-edge products and services that are ready for rapid deployment or adaptation to meet federal health requirements.